Movers

Sciensify
Why it movedMarkets
CGON

CG Oncology

Up on the dayUp +14.0%

Close
$84.78
Exchange
NASDAQ
Sources
4 linked

Why CG Oncology (CGON) Stock Rose 14.0% Today

CG Oncology (CGON) rose 14.0% after it said its Phase 3 bladder cancer trial PIVOT-006 met its primary endpoint.

By Muhammad Abdullah Riaz

2 min read

CG Oncology (CGON) shares rose 14.0% to $84.78 on Monday, November 16, 2026, after the company said its Phase 3 PIVOT-006 trial of cretostimogene met its primary endpoint. The company said cretostimogene resulted in a 68% reduction in the risk of recurrence compared with the control arm.

What happened

CG Oncology announced the topline results in a press release on November 16 and furnished the release to the SEC with a Form 8-K. The SEC filing index shows the 8-K was accepted at 8:15 a.m. that day.

The release describes cretostimogene as an investigational, intravesically delivered oncolytic immunotherapy. PIVOT-006 tested it in patients with intermediate risk and high grade Ta non muscle invasive bladder cancer (NMIBC) after complete tumor resection. The trial enrolled 367 patients across about 90 sites in the United States and Canada, and compared cretostimogene with surveillance.

The company said there were no Grade 3 or greater treatment related adverse events and no treatment related discontinuations. It said there are currently no FDA approved adjuvant treatment options for this population of approximately 50,000 patients.

The numbers

  • Close: $84.78, up 14.0% from $74.40 on November 13 (Nasdaq data)
  • Reduction in the risk of recurrence: 68%, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p less than 0.0001) (press release)
  • Median follow up: 17 months as of October 26, 2026 (press release)
  • Planned application: a second Biologics License Application (BLA), in intermediate risk and high grade Ta NMIBC, anticipated in the second quarter of 2027 (press release)

Context

The company also announced updated timing for its first BLA, in BCG unresponsive NMIBC, according to the Form 8-K. Based on FDA feedback, that submission will be broadened to include high grade papillary only disease, and the company anticipates completing it in March 2027.

The release says the PIVOT-006 topline results will be presented at the Society of Urologic Oncology Annual Meeting on December 2, 2026. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations for BCG unresponsive NMIBC. Its safety and efficacy have not been established by the FDA or any other health authority, the company said.

Sources

  1. CGON daily prices, November 13 and 16, 2026Nasdaqapi.nasdaq.com
  2. Press release: PIVOT-006 Phase 3 Registrational Trial results (Exhibit 99.1)CG Oncology, via SECsec.gov
  3. Form 8-K, CG Oncology, Inc., filed November 16, 2026SECsec.gov
  4. Filing index for the Form 8-K, with acceptance timeSECsec.gov
Filed under
  • CGON
  • CG Oncology
  • FDA
  • health care

Other movers on November 16

Each one explained, with sources.

The brief

More from Markets

All of Markets

Keep reading

All articles